Similar companies
Income Statement (USD)
| Q4 '25 | QoQ | |
|---|---|---|
| Operating expense | 6.8M | 37.5% |
| Net Income | -5.7M | 42.2% |
Balance Sheet (USD)
| Q4 '25 | QoQ | |
|---|---|---|
| Total Assets | 133M | 28.1% |
| Total Liabilities | 6.4M | 28.8% |
| Total Equity | 127M | 33.5% |
| Shares Outstanding | 93M | 7.9% |
Cash Flow (USD)
| Q4 '25 | QoQ | |
|---|---|---|
| Cash from operations | -7.2M | 16.9% |
| Cash from financing | 36M | 262.6% |
EPS
Financial Highlights for Anavex Life Sciences in Q4 '25
Operating Expenses for this period were 6.8M, showing a -37.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -5.7M, showing a 42.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
